Loading
RTOG 0617 is the trial that stopped dose escalation in lung cancer: patients given 74 Gy lived shorter than those given the standard 60 Gy, and cetuximab added nothing.
RTOG 0617 randomised 544 patients with stage III non-small-cell lung cancer receiving concurrent carboplatin-paclitaxel to 60 Gy or 74 Gy, with or without cetuximab. Median overall survival was 28.7 months with 60 Gy and 20.3 months with 74 Gy; the high-dose arm had more treatment-related deaths and higher heart dose, and cetuximab gave no benefit (Bradley and colleagues, Lancet Oncology 2015). The result fixed 60 Gy as the standard and drew attention to heart dose as a determinant of survival.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
544 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Median overall survivalprimary | 60 Gy | 217 | 28.7 months | - | - | - |
| 74 Gy | 207 | 20.3 months |
Shares Organs at risk and dose constraints, NRG Oncology, IMRT / IGRT (modern external beam) and the tag radiation-wave2.
Shares Chemoradiation (chemoradiotherapy, CRT), IMRT / IGRT (modern external beam) and the tag radiation-wave2.
Shares NRG Oncology, IMRT / IGRT (modern external beam) and the tag radiation-wave2.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag radiation-wave2.
Shares Radiosensitisers and the tag radiation-wave2.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag radiation-wave2.
Shares Non-small-cell lung cancer and the tag radiation-wave2.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave2.